جميع الدراسات
التوظيفرَصْدِيّ

Lysosomal Acid Lipase (LAL) Deficiency Registry

This study is a worldwide registry focusing on a rare genetic condition called Lysosomal Acid Lipase (LAL) Deficiency. This condition means the body struggles to break down certain fats, which can lead to various health problems, including liver issues. The registry aims to collect health information over time from people with LAL Deficiency to better understand the disease and how best to care for patients. It will also look at how effective treatments, like sebelipase alfa, are. Participation is entirely voluntary for both patients and doctors, and it's built to create a knowledge base that will help improve future treatment and support.

نظرة سريعة

الحالة
التوظيف
الراعي
Alexion Pharmaceuticals, Inc.
الهدف من التسجيل
300
ابدأ
30 May 2013
التاريخ المتوقع للانتهاء
30 Aug 2029

ما هو موضوع هذه الدراسة؟

Imagine your body as a busy factory with tiny clean-up crews called enzymes. In a rare condition called Lysosomal Acid Lipase (LAL) Deficiency, one of these clean-up enzymes isn't working properly. This enzyme is supposed to break down certain fats in your body. When it doesn't, these fats can build up in different organs, like the liver and spleen, causing health problems.

This condition can affect people differently. In babies, it's very serious and used to be called Wolman Disease. In older children and adults, it's often referred to as Cholesteryl Ester Storage Disease (CESD). In all cases, this build-up of fats can lead to issues such as liver damage, problems with blood cells, and difficulties absorbing nutrients from food. It can also increase the risk of heart and blood vessel problems.

Because LAL Deficiency is quite rare, doctors and researchers don't have all the answers yet. That's why this study, called the LAL Deficiency Registry, is so important. It's like a central database where information about many patients from around the world can be collected over time. By observing how the disease progresses, how it affects different people, and how various treatments work, the registry hopes to create a better understanding of LAL Deficiency. This knowledge will then be used to improve the care and support given to everyone living with this condition.

النقاط الرئيسية

  • It's a study aiming to understand a rare fat storage disorder called LAL Deficiency.
  • It collects ongoing health information from people with the condition worldwide.
  • It does not involve new treatments or medical procedures.
  • Its goal is to improve future care and treatment for LAL Deficiency patients.
  • Participation is completely voluntary and confidential.

من قد يكون مؤهلاً؟

To be part of this registry, you must have received a clear diagnosis from your doctor that confirms you have LAL Deficiency. Before you can officially join, you'll need to give your informed consent. This means a doctor or nurse will explain the study in detail, and you'll say yes (or your parent/guardian will say yes for you) to sharing your health information. This is a common and important step in all similar health registries to make sure you fully understand what's involved.

Another important point is that if you're currently taking part in a different clinical trial sponsored by a company called Alexion, you won't be able to join this registry at the same time. However, if you've already finished participating in an Alexion trial involving the medicine sebelipase alfa, you are welcome to join this registry. Also, being part of this registry won't stop you from joining another clinical trial in the future if you choose to.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. Do I have a confirmed diagnosis of LAL Deficiency?
  2. Am I willing to have my routine health information collected?
  3. Am I currently participating in another Alexion-sponsored clinical trial? (If yes, I cannot join now.)
  4. Am I over 18, or do I have a parent/guardian who can consent for me?
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

This is an observational study, which means you won't be given any new medicines or treatments as part of the registry itself. Instead, your medical information will be collected from your regular doctor's visits and medical records. This includes details about your diagnosis, symptoms, how your condition progresses over time, and any treatments you are already receiving, such as sebelipase alfa.

There won't be any extra appointments or specific tests required just for this registry. The information will be gathered during your routine medical care. The goal is to track your health journey over a long period to see how LAL Deficiency affects people and how different approaches to care work. The total duration of your participation depends on how long the registry continues and how long you wish to share your data.

المخاطر والفوائد المحتملة

Participating in this registry could offer potential benefits by helping researchers and doctors better understand LAL Deficiency, which could lead to improved care and treatments for all affected individuals in the future. There are very few direct risks to you as this is an observational study, meaning no new treatments or tests are involved beyond your usual care. The main consideration is ensuring the privacy of your health information, which the study aims to protect. You have the right to withdraw from the registry at any time, for any reason, and this decision will not affect your medical care.

Locations (104)

  • Clinical Trial Site
    الرمز البريدي المؤكد
    فينيكس، الولايات المتحدة· التوظيف
  • Clinical Trial Site
    الرمز البريدي المؤكد
    ستانفورد، الولايات المتحدة· التوظيف
  • Clinical Trial Site
    الرمز البريدي المؤكد
    Miramar, United States· التوظيف
  • Clinical Trial Site
    الرمز البريدي المؤكد
    أورلاندو، الولايات المتحدة· التوظيف
  • Clinical Trial Site
    الرمز البريدي المؤكد
    أتلانتا، الولايات المتحدة· التوظيف
  • Clinical Trial Site
    الرمز البريدي المؤكد
    شيكاغو، الولايات المتحدة· التوظيف
  • Clinical Trial Site
    الرمز البريدي المؤكد
    بوسطن، الولايات المتحدة· التوظيف
  • Clinical Trial Site
    الرمز البريدي المؤكد
    ديترويت، الولايات المتحدة· التوظيف
  • Clinical Trial Site
    الرمز البريدي المؤكد
    مينيابوليس، الولايات المتحدة· التوظيف
  • Clinical Trial Site
    الرمز البريدي المؤكد
    جاكسون، الولايات المتحدة· التوظيف
  • Clinical Trial Site
    الرمز البريدي المؤكد
    Hackensack, NJ, 7601, United States· التوظيف
  • Clinical Trial Site
    الرمز البريدي المؤكد
    نيويورك، الولايات المتحدة· التوظيف

أسئلة شائعة

What is LAL Deficiency?

It's a rare genetic condition where your body can't properly break down certain fats, causing them to build up in organs like the liver.

هل سأحصل على دواء جديد في هذه الدراسة؟

No, this is an observational study, meaning you won't be given new medicines or treatments as part of it. It collects information about your existing care.

Is my participation voluntary?

Yes, joining this registry is completely your choice (or your parents' choice if you're under 18) and you can leave at any time.

How will my health information be used?

Your de-identified health information will be used to better understand LAL Deficiency and improve care for others in the future.

هل سأحتاج إلى مواعيد إضافية مع الطبيب؟

No, data will be collected from your regular medical visits, so you won't need extra appointments specifically for this registry.

كيفية معرفة المزيد

Alexion Pharmaceuticals, Inc. (Sponsor)

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

هل أنت مهتم بالمشاركة؟

سجل اهتمامك

شارك تفاصيلك وفريق البحث لـ "Lysosomal Acid Lipase (LAL) Deficiency Registry… "سيتواصل معك إذا كنت مؤهلاً. تحدث دائمًا إلى طبيبك قبل الموافقة على المشاركة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.